Meito  Sangyo  Co., Ltd. Logo

Meito Sangyo Co., Ltd.

Produces food products and specialty chemicals for industrial and pharmaceutical applications.

2207 | T

Overview

Corporate Details

ISIN(s):
JP3920200007
LEI:
Country:
Japan
Address:
名古屋市西区笹塚町2丁目41番地
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Meito Sangyo Co., Ltd. is a diversified company primarily engaged in the manufacture and sale of food and chemical products, alongside a real estate business. The company's Food Division produces a variety of goods, including confectionery, beverages, seasonings, and food additives. Its Fine Chemicals Division specializes in creating unique products, such as polysaccharides (notably Dextrans) and enzymes, through microbial fermentation and chemical synthesis. These high-quality chemical products are supplied to various industries for applications including feed additives and pharmaceutical ingredients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 02:10
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.0 KB
2025-09-24 04:43
Regulatory News Service
訂正報告書(大量保有報告書・変更報告書)
Japanese 33.6 KB
2025-09-22 09:56
Major Shareholding Notification
大量保有報告書
Japanese 38.3 KB
2025-06-27 03:00
Regulatory News Service
臨時報告書
Japanese 26.6 KB
2025-06-25 06:14
Governance Information
内部統制報告書-第83期(2024/04/01-2025/03/31)
Japanese 26.1 KB
2025-06-25 06:12
Registration Form
確認書
Japanese 9.1 KB
2025-06-25 06:11
Registration Form
有価証券報告書-第83期(2024/04/01-2025/03/31)
Japanese 1.4 MB
2024-11-13 01:22
Interim Report
確認書
Japanese 9.0 KB
2024-11-13 01:21
Interim Report
半期報告書-第83期(2024/04/01-2025/03/31)
Japanese 226.5 KB
2024-07-16 09:13
Regulatory News Service
臨時報告書
Japanese 23.4 KB
2024-06-27 05:22
Post-Annual General Meeting Information
臨時報告書
Japanese 26.6 KB
2024-06-27 02:18
Governance Information
内部統制報告書-第82期(2023/04/01-2024/03/31)
Japanese 24.6 KB
2024-06-27 02:16
Registration Form
確認書
Japanese 9.1 KB
2024-06-27 02:14
Registration Form
有価証券報告書-第82期(2023/04/01-2024/03/31)
Japanese 1.2 MB
2024-05-13 09:22
Regulatory News Service
臨時報告書
Japanese 25.0 KB

Automate Your Workflow. Get a real-time feed of all Meito Sangyo Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Meito Sangyo Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Meito Sangyo Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America ADCT
Addex Therapeutics Ltd. Logo
Developing novel oral allosteric modulators to treat neurological disorders.
United States of America ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America ADIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.